<DOC>
	<DOCNO>NCT02908347</DOCNO>
	<brief_summary>This Phase IIa study design assess safety tolerability oral MP1032 patient moderate severe psoriasis period 6 week . Secondary endpoint evaluate clinical parameter psoriasis 6 week treatment period 4-week follow provide opportunity perform first assessment oral MP1032 's clinical efficacy treatment moderate severe psoriasis . The study population consist 44 enrol ( 40 complete ) patient moderate severe chronic plaque psoriasis . Patients must able provide write consent meet inclusion criterion none exclusion criterion .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Oral MP1032 Psoriasis Patients</brief_title>
	<detailed_description>This study randomize , double-blind , parallel , placebo-controlled exploratory pilot study evaluate safety , pharmacokinetics efficacy systemic oral ( po ) administration 100 mg MP1032 bid adult patient moderate severe chronic plaque psoriasis . The study design consist 28-day screening/run-in period , 42-day treatment period , 1 day End Treatment visit , 28-day follow-up period . Forty-four patient meet entry criterion randomize Day 1 1:1 ratio receive either 100 mg MP1032 placebo orally twice daily 42 day . The goal 40 patient ( 20 treatment group ) complete study . Pharmacokinetic sample occur 3 designate study day . Safety monitor signing informed consent form ( ICF ) last follow-up visit Day 71 . Efficacy assess 6 designate study day use follow assessment : PASI , PGA , DLQI , mNAPSI , EQ-5D 5L ( VAS ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Participants legally competent sign give inform consent . 2 . Adult male female patient age 18 65 year chronic plaque psoriasis : 1 . PASI score &gt; 10 screen 2 . Disease duration ≥ 6 month initiation study medication . 3 . Body Mass Index ( BMI ) 18.5 34.9 kg/m2 . 4 . Diagnosis chronic plaque psoriasis confirm dermatologist/physician . 5 . Women childbearing potential ( WCBP ) must negative urine pregnancy test Screening ( Visit 1 ) . In addition , sexually active WCBP must agree use 2 form adequate contraception throughout trial . 6 . Postmenopausal woman spontaneous amenorrhea least 12 month serum level follicle stimulate hormone ( FSH ) Levels indicate postmenopausal state per local laboratory reference range . Females hormone replacement therapy ( HRT ) whose menopausal status doubt must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study . Sterilized woman may include . 7 . Patients must meet follow clinical laboratory criterion : 1 . White blood cell count ≥ 3.5 x 10^9/L 2 . Platelet count ≥ 100 x 10^9/L 3 . Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) ; estimate glomerular filtration rate &gt; 60 mL/min 4 . Total bilirubin ≤ 1.5 x ULN 5 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) ≤ 1.5 x ULN 6 . Hemoglobin ≥ low limit normal per local laboratory reference range woman men accordingly 7 . No coagulopathy ( International Normalized Ratio [ INR ] &lt; 1.5 ) . 8 . Patients agree increase normal sun exposure course study . 9 . Patients able swallow 2 small capsule administration . 10 . Patients consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule , medication intake accord judgment Investigator . 1 . Patients nonplaque form psoriasis ( erythrodermic , guttate , pustular palmo plantar psoriasis ; severe form psoriasis arthritis , inverse form psoriasis ) . Mild moderate case psoriasis arthritis allow provide impact study objective determine Investigator . 2 . Patients druginduced psoriasis . 3 . Evidence skin condition time screen visit psoriasis would interfere evaluation effect study medication psoriasis . 4 . Patients serious medical condition , laboratory abnormality , psychiatric illness would prevent patient signing informed consent form . 5 . Pregnant lactating female females plan become pregnant study and/or within 28 day follow last dose study medication . 6 . Male patient plan partner pregnancy sperm donation study within 3 month follow last dose study medication . 7 . Known allergy mannitol , macrophage modulators , gelatin . 8 . Patients recent history current sign symptom , determine Investigator , severe , progressive viral bacterial infection , clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic insufficiency disease ( exclude psoriasis ) require systemic treatment major disease , well control may interfere conduct trial . 9 . Patients active malignancy history malignancy , except basal cell squamous cell carcinoma actinic keratosis . Basal cell carcinoma small squamous cell carcinoma skin excise accord guideline within last 5 year situ cervical carcinoma fully treat show evidence recurrence allow . 10 . Clinically significant abnormality 12lead electrocardiogram ( ECG ) screening . 11 . Positive human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C laboratory result . 12 . Previous strong sun exposure ( eg , sea holiday ) within 28 day study medication initiation . 13 . Known photo allergy and/or experience druginduced photo toxicity . 14 . Elective ( plan ) hospitalization medical intervention prevent patient follow protocol requirement . 15 . Prior Treatment : Drug class &gt; &gt; Last dose prior study medication initiation ( washout period ) Topical psoriasis medication ( include , limited corticosteroid , calcipotriene , topical vitamin D derivates , retinoids , coal tar ) &gt; &gt; 14 day Topical immunosuppressive drug ( tacrolimus , pimecrolimus , anthralin ) &gt; &gt; 14 day ( Exception : Nonmedicated emollient , moisturizers sunscreens allow ) , Use low potency topical steroid critical area face , genitalia , scalp may allow 24 hour prior randomization . Systemic treatment ( nonbiologic ) : Systemic immunosuppressant agent ( eg : methotrexate , cyclosporine , azathioprine ) , Systemic fumarate , Systemic corticosteroid &gt; &gt; 28 day Phototherapy photochemotherapy/photosensitizing drug &gt; &gt; 28 day Systemic retinoids &gt; &gt; 12 week Any investigational drug &gt; &gt; 24 week ( systemic ) ; 4 week ( topical ) Any AntiTNFs : Infliximab , adalimumab , golimumab , etanercept , etc . &gt; &gt; 12 week Other Biologics systemic therapy : Ustekimumab , alefacept , apremilast , Efalizumab , certolizumab pegol , secukinumab , etc . &gt; &gt; 24 week Rituximab &gt; &gt; 12 month 16 . Drinking ingest grapefruit , pomegranate , grapefruit juice grapefruit containing product within 14 day study medication initiation . 17 . Planned use ultraviolet ( UV ) phototherapy photochemotherapy/photosensitizing drug course study within 28 day follow last dose study medication . 18 . Patients history chronic alcohol drug abuse within 6 month study medication initiation . 19 . Patients employ MetrioPharm contract research organization ( CRO ) involve clinical study . 20 . Vulnerable patient ( eg , patient keep detention ) . 21 . Patients unable communicate , read understand local language , display condition , , Investigator 's opinion , make unsuitable clinical study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Plaque psoriasis</keyword>
	<keyword>chronic</keyword>
	<keyword>moderate</keyword>
	<keyword>severe</keyword>
	<keyword>Plaque</keyword>
</DOC>